Histogen, Inc., the regenerative medicine company that develops products derived from newborn fibroblasts, is apparently seeing some impressive results after conducting preliminary clinical trials of their HSC human hair regrowth product. These results were announced at this year’s ISHRS conference that took place in Amsterdam this past July. The buzz on the street is that Histogen just might be onto something big!
Craig L. Ziering, D.O., FAOCD, the principal investigator of the clinical trial will be joining us tonight to discuss his findings and to explain how Histogen’s HSC Human Hair Growth Product, might someday soon be used to effectively treat Androgenic Alopecia.
This is a show you won’t want to miss!
